ADVIC.PA
Advicenne S.A. [ADVIC.PA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ADVIC.PA Stock Summary
In the News
ADVIC.PA Financial details
Company Rating
Neutral
Market Cap
0
Income
-10.39M
Revenue
2.74M
Book val./share
-1.43
Cash/share
0.34
Dividend
-
Dividend %
-
Employees
32
Optionable
No
Shortable
Yes
Earnings
31 Mar 2022
P/E
-3.87
Forward P/E
-
PEG
1.85
P/S
-
P/B
3.14
P/C
19.12
P/FCF
-
Quick Ratio
3.31
Current Ratio
4.26
Debt / Equity
-1.2
LT Debt / Equity
-1.2
-
-
EPS (TTM)
-1.06
EPS next Y
-
EPS next Q
-
EPS this Y
-13.43%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
14.87%
Revenue last 5Y
19.85%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
16.67%
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-60%
ROE
-59%
ROC
-0.82%
Gross Margin
-543%
Oper. Margin
-733%
Profit Margin
-686%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.07-6.62
52W High
+8.33%
52W Low
+8.33%
RSI
-
Rel Volume
1.4
Avg Volume
45.76K
Volume
63.83K
Perf Week
0%
Perf Month
-
Perf Quarter
-
Perf Half Y
24.52%
-
-
-
-
Beta
1.43189
-
-
Volatility
0%, 0.25%
Prev Close
0%
Price
6.5
Change
-
ADVIC.PA Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.15 | 0.32 | 0.41 | 0.4 | 0.3 | |
| Net income per share | -0.58 | -1.74 | -1.76 | -1.34 | -1.16 | |
| Operating cash flow per share | -1.27 | -1.16 | -1.39 | -1.35 | -0.92 | |
| Free cash flow per share | -1.28 | -1.28 | -1.45 | -1.38 | -0.93 | |
| Cash per share | 3.26 | 2.31 | 1.99 | 1.37 | 0.95 | |
| Book value per share | 3.69 | 2.05 | 0.39 | 0.03 | -1.07 | |
| Tangible book value per share | 3.69 | 2.05 | 0.38 | 0.02 | -1.08 | |
| Share holders equity per share | 3.69 | 2.05 | 0.39 | 0.03 | -1.07 | |
| Interest debt per share | 0.05 | 0.21 | 1.1 | 1.32 | 1.71 | |
| Market cap | 52.24M | 53.04M | 54.83M | 60.29M | 64.52M | |
| Enterprise value | 26.43M | 36.86M | 38.06M | 47.61M | 56.2M | |
| P/E ratio | -11.3 | -3.74 | -3.69 | -4.85 | -5.63 | |
| Price to sales ratio | 43.9 | 20.53 | 15.71 | 16.16 | 21.92 | |
| POCF ratio | -5.13 | -5.6 | -4.69 | -4.81 | -7.05 | |
| PFCF ratio | -5.06 | -5.1 | -4.47 | -4.7 | -6.97 | |
| P/B Ratio | 1.76 | 3.17 | 16.76 | 195.12 | -6.08 | |
| PTB ratio | 1.76 | 3.17 | 16.76 | 195.12 | -6.08 | |
| EV to sales | 22.21 | 14.26 | 10.9 | 12.76 | 19.1 | |
| Enterprise value over EBITDA | -4.98 | -2.64 | -2.72 | -3.95 | -5.69 | |
| EV to operating cash flow | -2.6 | -3.89 | -3.25 | -3.8 | -6.14 | |
| EV to free cash flow | -2.56 | -3.54 | -3.1 | -3.71 | -6.07 | |
| Earnings yield | -0.09 | -0.27 | -0.27 | -0.21 | -0.18 | |
| Free cash flow yield | -0.2 | -0.2 | -0.22 | -0.21 | -0.14 | |
| Debt to equity | 0.01 | 0.1 | 2.83 | 39.74 | -1.6 | |
| Debt to assets | 0.01 | 0.07 | 0.39 | 0.65 | 1.19 | |
| Net debt to EBITDA | 4.87 | 1.16 | 1.2 | 1.05 | 0.84 | |
| Current ratio | 12.64 | 3.85 | 1.83 | 2.72 | 1.59 | |
| Interest coverage | -545.63 | -2.3K | 0 | 0 | 0 | |
| Income quality | 2.2 | 0.67 | 0.79 | 1.01 | 0.8 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 1.38 | 1.39 | 1.26 | 1.29 | |
| Research and developement to revenue | 0 | 3.31 | 2.33 | 2.4 | 2.4 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.01 | 0.1 | 0.05 | 0.02 | 0.01 | |
| Capex to revenue | -0.12 | -0.36 | -0.16 | -0.08 | -0.04 | |
| Capex to depreciation | -1.08 | -3.06 | -2.65 | -0.73 | -0.29 | |
| Stock based compensation to revenue | 0.42 | 0.2 | 0.17 | 0.09 | 0.16 | |
| Graham number | 6.91 | 8.96 | 3.92 | 1 | 5.27 | |
| ROIC | -0.16 | -0.73 | -1.14 | -0.99 | -1.58 | |
| Return on tangible assets | -0.14 | -0.59 | -0.62 | -0.66 | -0.81 | |
| Graham Net | 2.85 | 1.51 | -0.35 | -0.53 | -1.43 | |
| Working capital | 29.94M | 16.02M | 9.42M | 10.51M | 4.49M | |
| Tangible asset value | 29.63M | 16.72M | 3.23M | 142K | -10.75M | |
| Net current asset value | 28.97M | 14.48M | 57K | -1.96M | -12.79M | |
| Invested capital | 0.01 | 0.1 | 2.83 | 39.74 | -1.6 | |
| Average receivables | 0 | 276.5K | 685.5K | 810K | 945K | |
| Average payables | 1.53M | 2.79M | 4.17M | 3.68M | 2.16M | |
| Average inventory | 327.33K | 452.2K | 615.5K | 726K | 849.5K | |
| Days sales outstanding | 0 | 78.11 | 85.53 | 78.48 | 134.94 | |
| Days payables outstanding | 72.05 | 2.06K | 1.83K | 1.1K | 454.21 | |
| Days of inventory on hand | 17.63 | 262 | 302.79 | 268.97 | 320.89 | |
| Receivables turnover | 0 | 4.67 | 4.27 | 4.65 | 2.7 | |
| Payables turnover | 5.07 | 0.18 | 0.2 | 0.33 | 0.8 | |
| Inventory turnover | 20.71 | 1.39 | 1.21 | 1.36 | 1.14 | |
| ROE | -0.16 | -0.85 | -4.54 | -40.22 | 1.08 | |
| Capex per share | -0.02 | -0.11 | -0.07 | -0.03 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2020-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.05 | 0.05 | 0.09 | 0.09 | |
| Net income per share | 0 | -0.34 | -0.34 | -0.19 | -0.19 | |
| Operating cash flow per share | 0 | -0.2 | -0.2 | -0.19 | -0.19 | |
| Free cash flow per share | 0 | -0.2 | -0.2 | -0.22 | -0.22 | |
| Cash per share | 0 | 0.95 | 0.95 | 0.34 | 0.34 | |
| Book value per share | 0 | -1.07 | -1.07 | -1.43 | -1.43 | |
| Tangible book value per share | 0 | -1.08 | -1.08 | -1.46 | -1.46 | |
| Share holders equity per share | 0 | -1.07 | -1.07 | -1.43 | -1.43 | |
| Interest debt per share | 0 | 1.72 | 1.72 | 1.72 | 1.72 | |
| Market cap | 0 | 64.51M | 64.51M | 64.49M | 64.49M | |
| Enterprise value | -8.75M | 56.18M | 56.18M | 61.08M | 61.08M | |
| P/E ratio | 0 | -4.84 | -4.84 | -8.64 | -8.64 | |
| Price to sales ratio | 0 | 124.41 | 124.41 | 75.79 | 75.79 | |
| POCF ratio | 0 | -32.11 | -32.11 | -34.78 | -34.78 | |
| PFCF ratio | 0 | -32.16 | -32.16 | -29.76 | -29.76 | |
| P/B Ratio | 0 | -6.08 | -6.08 | -4.54 | -4.54 | |
| PTB ratio | 0 | -6.08 | -6.08 | -4.54 | -4.54 | |
| EV to sales | 0 | 108.36 | 108.36 | 71.77 | 71.77 | |
| Enterprise value over EBITDA | 0 | -19.93 | -19.93 | -42.11 | -42.11 | |
| EV to operating cash flow | 0 | -27.97 | -27.97 | -32.93 | -32.93 | |
| EV to free cash flow | 0 | -28.01 | -28.01 | -28.18 | -28.18 | |
| Earnings yield | 0 | -0.05 | -0.05 | -0.03 | -0.03 | |
| Free cash flow yield | 0 | -0.03 | -0.03 | -0.03 | -0.03 | |
| Debt to equity | 0.96 | -1.6 | -1.6 | -1.2 | -1.2 | |
| Debt to assets | 0.36 | 1.19 | 1.19 | 1.6 | 1.6 | |
| Net debt to EBITDA | 0 | 2.95 | 2.95 | 2.36 | 2.36 | |
| Current ratio | 3.42 | 1.59 | 1.59 | 1.05 | 1.05 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 0 | 0.6 | 0.6 | 0.99 | 0.99 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 1.75 | 1.75 | 0.96 | 0.96 | |
| Research and developement to revenue | 0 | 3.84 | 3.84 | 1.14 | 1.14 | |
| Intangibles to total assets | 0 | 0.01 | 0.01 | 0.02 | 0.02 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0.17 | 0.17 | |
| Capex to revenue | 0 | 0.01 | 0.01 | -0.37 | -0.37 | |
| Capex to depreciation | 0 | 0.06 | 0.06 | -6.07 | -6.07 | |
| Stock based compensation to revenue | 0 | 0.29 | 0.29 | 0.1 | 0.1 | |
| Graham number | 0 | 2.84 | 2.84 | 2.46 | 2.46 | |
| ROIC | 0 | -0.45 | -0.45 | -0.51 | -0.51 | |
| Return on tangible assets | 0 | -0.24 | -0.24 | -0.18 | -0.18 | |
| Graham Net | 0 | -1.43 | -1.43 | -1.98 | -1.98 | |
| Working capital | 15.79M | 4.49M | 4.49M | 402K | 402K | |
| Tangible asset value | 9.43M | -10.75M | -10.75M | -14.44M | -14.44M | |
| Net current asset value | 6.84M | -12.79M | -12.79M | -16.8M | -16.8M | |
| Invested capital | 0.96 | -1.6 | -1.6 | -1.2 | -1.2 | |
| Average receivables | 0 | 0 | 1.09M | 1.24M | 1.38M | |
| Average payables | 0 | 0 | 1.39M | 1.23M | 1.08M | |
| Average inventory | 0 | 0 | 982K | 1.33M | 1.67M | |
| Days sales outstanding | 0 | 188.85 | 188.85 | 146.16 | 146.16 | |
| Days payables outstanding | 0 | 499.4 | 499.4 | 339.47 | 339.47 | |
| Days of inventory on hand | 0 | 352.81 | 352.81 | 526.74 | 526.74 | |
| Receivables turnover | 0 | 0.48 | 0.48 | 0.62 | 0.62 | |
| Payables turnover | 0 | 0.18 | 0.18 | 0.27 | 0.27 | |
| Inventory turnover | 0 | 0.26 | 0.26 | 0.17 | 0.17 | |
| ROE | 0 | 0.31 | 0.31 | 0.13 | 0.13 | |
| Capex per share | 0 | 0 | 0 | -0.03 | -0.03 |
ADVIC.PA Frequently Asked Questions
What is Advicenne S.A. stock symbol ?
Advicenne S.A. is a FR stock , located in Nimes of Occitanie and trading under the symbol ADVIC.PA
What is Advicenne S.A. stock quote today ?
Advicenne S.A. stock price is $6.5 today.
Is Advicenne S.A. stock public?
Yes, Advicenne S.A. is a publicly traded company.
Company Profile
- Volume Average 45.76K
- Employee 32
- CEO Dr. Andr Ulmann M.D., Ph.D.
- Headquarters Nimes,OCCITANIE,FR
- IPO Date 2017-12-06
-
Website
https://www.advicenne.com 
Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.
